{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028614","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-06-15T12:00:45+00:00","discovered_at":"2026-06-15T12:05:16.426500+00:00","generated_at":"2026-06-15T12:06:57.935091+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Telomir Pharma publishes preclinical data showing Telomir-Zn reverses insulin resistance in T2DM zebrafish model","bullets":["Telomir-Zn reduced HOMA-IR from ~10-12 to ~3 after 14 days in diet-induced T2DM zebrafish model.","Treatment produced dose-dependent improvements in fasting glucose, glucose tolerance, and fasting insulin levels.","This is the second peer-reviewed publication on Telomir-Zn in 2026, supporting its metal-homeostasis mechanism.","Telomir-Zn has FDA IND clearance for a Phase 1/2 trial in triple-negative breast cancer (TELO-001)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028614","json":"https://secwatch.observer/filing/0001493152-26-028614.json","markdown":"https://secwatch.observer/filing/0001493152-26-028614.md","text":"https://secwatch.observer/filing/0001493152-26-028614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226028614/0001493152-26-028614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226028614/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:06:57.935091+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}